Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

NCT01438554 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors
Thyroid Cancer
Soft-tissue Sarcoma
Cholangiocarcinoma

Interventions

DRUG: Pazopanib
DRUG: GSK1120212

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]